SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending downwards amid concerns about market overvaluation and potential economic impacts from a possible government shutdown. Community members are debating whether this pullback is a healthy correction or the start of a larger downturn, with some citing bearish signals like repo market activity, while others suggest dip-buying opportunities still exist.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as community members debate whether a post-earnings dip signals an overvalued stock or a buying opportunity. Some traders point to Michael Burry's reported short position as a bearish signal, while others highlight the company's growth and potential in the AI sector. Discussions also include CEO Alex Karp's commentary and its potential impact on the stock.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The QQQ is trending amid market volatility and discussions around AI's monetization timeline, drawing mixed reactions from traders. Community members are debating the significance of the current pullback, with some eyeing dip-buying opportunities while others express concern about a potential bubble. Broader economic factors, including potential government shutdowns and their impacts, also appear to be influencing market sentiment.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards, with community members expressing concerns about a potential market correction and the company's AI spending. Some traders are actively shorting the stock, while others view the dip as a buying opportunity, noting the company's strong fundamentals. Overall, sentiment is mixed as investors assess META's future prospects amidst broader market uncertainty.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as the community debates its valuation and potential market correction, especially in light of Michael Burry's bets against the stock. Discussions revolve around the company's strong position in the AI sector versus concerns about a possible AI bubble and impact from geopolitical factors like China trade relations. Bullish sentiment remains fueled by new partnerships, price target increases, and overall AI hype.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amid market volatility and discussions around its correlation with Ethereum's price movements, especially after a reported hack in the crypto space. Community chatter includes debates on analyst Tom Lee's predictions and the impact of potential government actions on crypto, with some expressing concerns about recent losses while others remain optimistic about the long-term prospects tied to Ethereum's growth.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as community members assess its correlation to Bitcoin's price movement and debate whether recent earnings justify its valuation; some express concern over potential downside risk amid overall crypto market volatility, while others point to positive catalysts like potential S&P 500 inclusion.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a significant after-hours drop following earnings, despite beating expectations. Community discussions revolve around trial data for PMO therapies and their potential impact on future revenue, with some suggesting the sell-off is overblown and driven by short manipulation, while others express concern over management and future prospects. The long-term potential of Elevidys as a replacement for older treatments is also a key talking point.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid community discussion about a recent price drop and its potential implications, with some analysts suggesting it reflects bullish sentiment as users move coins to personal wallets. Contrasting views circulate, with some warning about BTC's resilience during economic tests compared to gold, while others remain bullish, citing healthy inflows and institutional buying.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid discussions about upcoming token unlocks and their potential impact on the project's utility and price, with some community members expressing concerns about dilution. Despite the concerns, bullish investors cite partnerships, staking rewards, and the potential of the Super App as reasons to remain optimistic about ZBCN's long-term prospects. Ongoing debates about a specific user and allegations of fraudulent activity are also contributing to the heightened discussion.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer plays hardball in weight-loss drug fight

Pfizer has filed two lawsuits to block Novo Nordisk's $9bn bid to buy Metsera...

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul><p>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.</p><h2 class="st-heading-2"><strong>Revenue And Subscriber Growth Remain Strong</strong></h2><p>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.</p><p>Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.</p><p>Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.</p><h2 class="st-heading-2"><strong>Talks With Novo Nordisk</strong></h2><p>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.</p><p>The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.</p><h2 class="st-heading-2"><strong>Outlook For 2025</strong></h2><p>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.</p><p>For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.</p><h2 class="st-heading-2"><strong>Stocktwits Traders Bet On Further Gains</strong></h2><p>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure><p>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;</p><p><stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl></p><p>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.</p><p><stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl></p><p><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl></p><p><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Equity

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market...

<ul class="summary-bullets"><li>The new lawsuit alleges that Novo Nordisk’s proposed transaction violates several laws due to the anticompetitive effects it would have on the GLP-1 drug market.</li><li>It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.</li><li>Pfizer added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward.<br>&nbsp;</li></ul><p>Pfizer Inc. (PFE) on Monday announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.</p><p>The lawsuit alleges that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by the company to protect its dominant market position in GLP-1 drugs by capturing and killing a nascent American competitor before it gains the support of Pfizer.</p><h2 class="st-heading-2">What Does The New Lawsuit Say?</h2><p>The new lawsuit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251102755714/en/Pfizer-Files-Federal-Antitrust-Claims-in-Second-Lawsuit-Against-Metsera-its-Controlling-Stockholders-and-Novo-Nordisk">alleges</a> that Novo Nordisk’s proposed transaction violates several laws because of the anticompetitive effects it would have in the GLP-1 drug markets and negatively impact patients who suffer from obesity, diabetes, and other metabolic conditions. It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.</p><p>Pfizer further added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward.</p><p>“Metsera’s and its controlling stockholders’ actions, as well as those of Novo Nordisk, are in clear violation of the antitrust laws. We are confident in the merits of our case and look forward to presenting it to the Court,” the company said.</p><p>Pfizer also filed a separate lawsuit last week against Metsera, its Board of Directors, and Novo Nordisk in the Delaware Court of Chancery, asserting claims for breach of contract and fiduciary duty. It has also filed a motion with the Court of Chancery requesting that it issue a temporary restraining order to block Metsera from terminating the merger agreement with itself. &nbsp;</p><h2 class="st-heading-2">What Sparked The Legal Battle?</h2><p>Danish drugmaker Novo Nordisk (NVO) announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) <a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">agreement</a> to acquire the smaller obesity biopharmaceutical company in September.</p><p>Metsera subsequently gave Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.</p><p>Pfizer, however, maintains that Novo's offer cannot be considered a superior proposal, given the significant regulatory risk, among other factors.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>MTSR stock has more than doubled this year.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/serina-therapeutics-stock-slumps-premarket-after-fda-place-hold-on-application-to-initiate-clinical-trials-for-experimental-therapy/cL2NcnCR3zB">Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit 

Pfizer filed the lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S, alleging that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action. 

MIKE DAVIS: Foreign weight-loss drugmaker seeks fat profits by gobbling up American upstart

'Something is rotten in the state of Denmark,' as Hamlet said in Shakespeare's time. It was true then, and it's true today.While Senate Democrats are holding our government hostage to their...

Global week ahead: Is Novo Nordisk past 'peak uncertainty'?

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months...

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul><p>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.</p><h2 class="st-heading-2"><strong>Canaccord Starts Coverage With ‘Buy’&nbsp;</strong></h2><p>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.</p><p>Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.</p><h2 class="st-heading-2"><strong>Pfizer And Novo Nordisk Fuel M&amp;A Speculation</strong></h2><p><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.</p><p>Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.</p><h2 class="st-heading-2"><strong>Viking’s Obesity Drug Program</strong></h2><p>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.</p><p>Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.</p><h2 class="st-heading-2"><strong>Q3 Earnings And Outlook</strong></h2><p>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.</p><p>The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;</p><p>Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.</p><h2 class="st-heading-2"><strong>Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</strong></h2><p>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure><p>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.</p><p><stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl></p><p>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.</p><p><stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl></p><p><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Mizuho's Holtz talks what is behind Novo's bid for Metsera

Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S